CONMED Corporation Announces First Quarter 2023 Financial Results

Rhea-AI Summary

CONMED Corporation (NYSE: CNMD) reported strong first quarter results for 2023, achieving sales of $295.5 million, a 21.9% increase year over year, with a 25.1% rise in constant currency. Domestic sales grew by 25.4%, while international sales rose 17.8% year over year. However, diluted net earnings per share (GAAP) fell to $0.06, an 87.2% decline compared to Q1 2022. Adjusted diluted net earnings per share decreased by 5.7% to $0.66. The company has raised its full-year revenue guidance to between $1.205 billion and $1.250 billion, up from a previous range of $1.170 billion to $1.220 billion. Additionally, adjusted diluted net earnings per share guidance was increased to a range of $3.30 to $3.50.

Positive

• Sales increased by 21.9% year over year to $295.5 million.
• Domestic revenue grew by 25.4% year over year.
• International revenue increased by 17.8%, or 24.7% in constant currency.
• Raised full-year 2023 revenue guidance to $1.205 billion - $1.250 billion.
• Increased adjusted diluted EPS guidance range to $3.30 - $3.50.

Negative

• Diluted net earnings per share (GAAP) decreased 87.2% to $0.06 compared to Q1 2022.
• Adjusted diluted net earnings per share decreased 5.7% to $0.66.

LARGO, Fla.--(BUSINESS WIRE)-- CONMED Corporation (NYSE: CNMD) today announced financial results for the first quarter ended March 31, 2023.

First Quarter 2023 Highlights

• Sales of $295.5 million increased 21.9% year over year as reported and 25.1% in constant currency. Acquisitions contributed approximately 570 basis points of growth.
• Domestic revenue increased 25.4% year over year.
• International revenue increased 17.8% year over year as reported and 24.7% in constant currency.
• Diluted net earnings per share (GAAP) were $0.06, a decrease of 87.2% compared to the first quarter of 2022.
• Adjusted diluted net earnings per share⁽¹⁾ were $0.66, a decrease of 5.7% compared to the first quarter of 2022.

“I am proud of our team for driving excellent first quarter results and staying focused on serving our customers,” commented Curt R. Hartman, CONMED’s Chair of the Board, President, and Chief Executive Officer. “Our strong first quarter provides a very solid start to the year, and the team is focused on execution and delivering on our increased outlook.”

2023 Outlook

Based on the first quarter results, the Company is raising its revenue guidance for the full year 2023 and now expects revenue between $1.205 billion and $1.250 billion, compared to its prior guidance of between $1.170 billion and $1.220 billion. This range continues to include an expected headwind from foreign exchange of between 150 and 200 basis points.

The Company now expects full-year 2023 adjusted diluted net earnings per share⁽²⁾ in the range of $3.30 to $3.50, compared to its prior range of $3.20 to $3.45. This range continues to include an expected headwind from foreign exchange of between $0.20 and $0.25.

Supplemental Financial Disclosures

⁽¹⁾ A reconciliation of reported diluted net earnings per share to adjusted diluted net earnings per share, a non-GAAP financial measure, appears below.

⁽²⁾ Information reconciling forward-looking adjusted diluted net earnings per share to the comparable GAAP financial measures is unavailable to the company without unreasonable effort, as discussed below.

Conference Call

The Company’s management will host a conference call today at 4:30 p.m. ET to discuss its first quarter 2023 results.

To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode.

This conference call will also be webcast and can be accessed from the “Investors” section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

Consolidated Condensed Statements of Income
(in thousands except per share amounts, unaudited)
	Three Months Ended
	March 31,
	2023			2022
Net sales	$	295,468		$	242,327
Cost of sales		140,147			106,336
Gross profit		155,321			135,991
% of sales		52.6	%		56.1	%
Selling & administrative expense		130,083			102,875
Research & development expense		12,539			10,672
Income from operations		12,699			22,444
% of sales		4.3	%		9.3	%
Interest expense		10,255			4,998
Income before income taxes		2,444			17,446
Provision for income taxes		625			2,471
Net income	$	1,819		$	14,975
Basic EPS	$	0.06		$	0.51
Diluted EPS		0.06			0.47
Basic shares		30,511			29,428
Diluted shares		31,204			35,155

Sales Summary
(in millions, unaudited)
	Three Months Ended March 31,
								% Change
															Domestic			International
	2023			2022				As Reported		Impact of Foreign Currency		Constant Currency			As Reported			As Reported		Impact of Foreign Currency		Constant Currency
Orthopedic Surgery	$	131.2		$	107.5			22.0	%	4.0	%	26.0	%		29.0	%		18.2	%	6.1	%	24.3	%
General Surgery		164.3			134.8			21.9	%	2.5	%	24.4	%		24.0	%		17.1	%	8.4	%	25.5	%
	$	295.5		$	242.3			21.9	%	3.2	%	25.1	%		25.4	%		17.8	%	6.9	%	24.7	%
Single-use Products	$	249.3		$	201.5			23.7	%	3.2	%	26.9	%		28.9	%		17.3	%	7.1	%	24.4	%
Capital Products		46.2			40.8			13.0	%	3.3	%	16.3	%		5.5	%		19.8	%	6.2	%	26.0	%
	$	295.5		$	242.3			21.9	%	3.2	%	25.1	%		25.4	%		17.8	%	6.9	%	24.7	%
Domestic	$	164.6		$	131.2			25.4	%	0.0	%	25.4	%
International		130.9			111.1			17.8	%	6.9	%	24.7	%
	$	295.5		$	242.3			21.9	%	3.2	%	25.1	%

Reconciliation of Reported Net Income to Adjusted Net Income
(in thousands, except per share amounts, unaudited)
	Three Months Ended March 31, 2023
	Gross Profit			Selling & Administrative Expense			Operating Income			Interest Expense			Tax Expense		Effective Tax Rate		Net Income		Basic EPS		Adjustments		Diluted EPS
As reported	$	155,321		$	130,083		$	12,699		$	10,255		$	625	25.6	%	$	1,819			$	-	$	1,819
% of sales		52.6	%		44.0	%		4.3	%
EPS																			$	0.06			$	0.06
Shares																				30,511		693		31,204
Acquisition and integration costs(1)		2,096			(448	)		2,544			-			654				1,890
Restructuring and related costs(2)		2,035			(1,578	)		3,613			-			930				2,683
Software implementation costs(3)		-			(4,259	)		4,259			-			1,096				3,163
Contingent consideration fair value adjustments(4)		-			(4,436	)		4,436			-			1,141				3,295
	$	159,452		$	119,362		$	27,551		$	10,255		$	4,446			$	12,850
Adjusted gross profit %		54.0	%
Amortization(5)	$	1,500			(7,265	)		8,765			(1,506	)		2,530				7,741
As adjusted				$	112,097		$	36,316		$	8,749		$	6,976	25.3	%	$	20,591			$	-	$	20,591
% of sales					37.9	%		12.3	%
Adjusted diluted EPS																							$	0.66
Shares																				30,511		693		31,204
Convertible note hedges(6)																								(64	)
Adjusted diluted shares																								31,140
	Three Months Ended March 31, 2022
	Gross Profit			Selling & Administrative Expense			Operating Income			Interest Expense			Tax Expense		Effective Tax Rate		Net Income		Basic EPS		Adjustments(7)		Diluted EPS
As reported	$	135,991		$	102,875		$	22,444		$	4,998		$	2,471	14.2	%	$	14,975			$	1,715	$	16,690
% of sales		56.1	%		42.5	%		9.3	%
EPS																			$	0.51			$	0.47
Shares																				29,428		5,727		35,155
	$	135,991		$	102,875		$	22,444		$	4,998		$	2,471			$	14,975
Adjusted gross profit %		56.1	%
Amortization(5)	$	1,500			(6,562	)		8,062			(880	)		2,160				6,782
As adjusted				$	96,313		$	30,506		$	4,118		$	4,631	17.5	%	$	21,757			$	1,715	$	23,472
% of sales					39.7	%		12.6	%
Adjusted diluted EPS																							$	0 .70
Shares																				29,428		5,727		35,155
Convertible note hedges(6)																								(1,412	)
Adjusted diluted shares																								33,743

(1) In 2023, the Company incurred charges related to the amortization of inventory step-up to fair value associated with the acquisition of In2Bones Global, Inc. and integration costs and professional fees associated with the acquisitions of In2Bones Global, Inc. and Biorez, Inc.

(2) In 2023, the Company incurred consulting fees related to an operational cost improvement initiative and severance related to the elimination of certain positions.

(3) In 2023, the Company incurred additional freight, labor and travel costs as well as professional fees related to the implementation of a warehouse management software.

(4) In 2023, the Company incurred expense related to the fair value adjustments to contingent consideration.

(5) Includes amortization of intangible assets and deferred financing fees.

(6) Non-GAAP adjusted dilutive weighted average shares outstanding exclude dilution that is expected to be offset by the Company’s convertible notes hedge transactions.

(7) The Company adopted ASU 2020-06, effective January 1, 2022. As a result of the adoption, the Company is required to compute diluted EPS using the if-converted method. Under the if-converted method, the numerator is adjusted for interest expense applicable to its convertible notes (net of tax) and the denominator includes additional common shares assuming conversion premium and principal portion of the notes (when permitted or required) are settled in shares. Subsequent to June 6, 2022, the Company is required to settle the principal value of its convertible notes in cash.

Reconciliation of Reported Net Income to EBITDA & Adjusted EBITDA
(in thousands, unaudited)
		Three Months Ended
		March 31,
		2023			2022
Net income		$	1,819		$	14,975
Provision for income taxes			625			2,471
Interest expense			10,255			4,998
Depreciation			4,057			4,032
Amortization			13,877			12,799
EBITDA		$	30,633		$	39,275
Stock based compensation			5,726			4,463
Acquisition and integration costs			2,544			-
Restructuring and related costs			3,613			-
Software implementation costs			4,259			-
Contingent consideration fair value adjustments			4,436			-
Adjusted EBITDA		$	51,211		$	43,738
EBITDA Margin
EBITDA			10.4	%		16.2	%
Adjusted EBITDA			17.3	%		18.0	%

About CONMED Corporation

CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com.

Forward-Looking Statements

This press release and the associated conference call may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2022. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.

Supplemental Information - Reconciliation of GAAP to Non-GAAP Financial Measures

The Company supplements the reporting of its financial information determined under generally accepted accounting principles in the United States (GAAP) with certain non-GAAP financial measures, including percentage sales growth in constant currency; adjusted gross profit; cost of sales excluding specified items; adjusted selling and administrative expenses; adjusted operating income; adjusted interest expense; adjusted income tax expense; adjusted effective income tax rate; adjusted net income, adjusted diluted shares and adjusted diluted net earnings per share (EPS). The Company believes that these non-GAAP measures provide meaningful information to assist investors and shareholders in understanding its financial results and assessing its prospects for future performance. Management believes percentage sales growth in constant currency and the other adjusted measures described above are important indicators of its operations because they exclude items that may not be indicative of, or are unrelated to, its core operating results and provide a baseline for analyzing trends in the Company’s underlying business. Further, the presentation of EBITDA is a non-GAAP measurement that management considers useful for measuring aspects of the Company’s cash flow. Management uses these non-GAAP financial measures for reviewing the operating results and analyzing potential future business trends in connection with its budget process and bases certain management incentive compensation on these non-GAAP financial measures.

Net sales on a constant currency basis is a non-GAAP measure. The Company analyzes net sales on a constant currency basis to better measure the comparability of results between periods. To measure percentage sales growth in constant currency, the Company removes the impact of changes in foreign currency exchange rates that affect the comparability and trend of net sales. To measure earnings performance on a consistent and comparable basis, the Company excludes certain items that affect the comparability of operating results and the trend of earnings. These adjustments are irregular in timing, may not be indicative of past and future performance and are therefore excluded to allow investors to better understand underlying operating trends.

Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies' non-GAAP financial measures having the same or similar names. These adjusted financial measures should not be considered in isolation or as a substitute for reported sales growth, gross profit, cost of sales, selling and administrative expenses, operating income, interest expense, income tax expense, effective income tax rate, net income, diluted shares and diluted net earnings per share, the most directly comparable GAAP financial measures. These non-GAAP financial measures are an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures above, provide a more complete understanding of the business. The Company strongly encourages investors and shareholders to review its financial statements and publicly filed reports in their entirety and not to rely on any single financial measure.

We are unable to present a quantitative reconciliation of our expected diluted net earnings per share to expected adjusted diluted net earnings per share as we are unable to predict with reasonable certainty and without unreasonable effort the impact and timing of acquisition, integration and other charges. The financial impact of these items is uncertain and is dependent on various factors, including timing, and could be material to our consolidated condensed statements of income.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230426005748/en/

CONMED Corporation

Todd W. Garner

Chief Financial Officer

727-214-2975

ToddGarner@conmed.com

Source: CONMED Corporation

FAQ

What were CONMED's Q1 2023 sales figures, and how do they compare year over year?

CONMED's Q1 2023 sales were $295.5 million, a 21.9% increase year over year.

What is the full-year revenue guidance for CONMED in 2023?

CONMED raised its revenue guidance for 2023 to between $1.205 billion and $1.250 billion.

How much did CONMED's diluted net earnings per share decrease in Q1 2023?

Diluted net earnings per share (GAAP) decreased 87.2% to $0.06 in Q1 2023.

What is the adjusted diluted EPS guidance for CONMED in 2023?

CONMED's adjusted diluted EPS guidance for 2023 is now between $3.30 and $3.50.